论文部分内容阅读
目的 通过体外药物敏感试验评价来立信的抗结核作用。方法 将来立信纯品粉稀释成 (5、 5 0 ) μg/m l高低两种浓度 ,按常规行结核分枝杆菌的药物敏感试验 ,凡在低浓度含药培养基上生长 2 0个以上菌落或占培养基斜面 1/ 4者为耐药。结果 188株结核分枝杆菌 ,初治 15 2株耐来立信为 0 ;复治 36株 ,耐来立信为 5 .5 6 %。结论 来立信具有良好抗结核分枝杆菌的作用 ,耐药率低 ,安全性好 ,可成为 MDR- TB有效的治疗药物之一。
Objective To evaluate the anti-tuberculosis effect of Ericsson by in vitro drug sensitivity test. Methods In the future, the pure powder of Ericsson was diluted to two levels of (5, 50) μg / ml. According to the routine drug sensitivity test of Mycobacterium tuberculosis, 20 or more colonies were grown on low concentration drug-containing medium Incubation medium slope 1/4 were resistant. Results 188 strains of Mycobacterium tuberculosis, newly diagnosed 15 2 resistant to Ericsson 0; retreatment 36, resistant to Ericsson was 5.56%. Conclusion Lixin has a good anti-Mycobacterium tuberculosis effect, low resistance rate, good safety and can be one of MDR-TB effective drugs.